MediPress Health-Limited Partnership Partnership Units
TTASE:MPRS52.00
ILA
-3.80
(-6.81%)
ISIN
IL0011828980
Return %
Stock
S&P 500
1Y
-18.11
14.20
3Y
-11.11
81.12
5Y
-92.96
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Joseph Press
- Full Time Employees
- 11,900
- Sector
- Technology services
- Industry
- Packaged software
- Address
- 40 Tuval Street Ramat Gan TA Israel 5252247
- IPO Date
- Dec 30, 2021
- Website
- matrix.co.il
- Similar Companies
- Business
- MediPress Health-Limited Partnership (MPRS.TA) operates as a research and development life science partnership and venture capital firm specializing in seed and startup investments in medical research and development companies; it focuses on innovative technologies including digital medicine, artificial intelligence applications in healthcare, medical equipment, remote diagnostics, and treatment solutions. The firm invests in portfolio companies developing proton radiation therapy for cancer treatment and non-surgical vaginal solutions for pelvic floor disorders in women; it seeks board positions in its investees to support strategic growth. Founded in 2021 and headquartered in Ramat Gan, Israel, MediPress targets early-stage medtech ventures primarily in Israel with potential for global operations. In January 2022, MediPress participated in the Series D investment round of P-Cure Ltd., a developer of compact adaptive proton therapy systems, and appointed CEO Prof. Joseph Press to P-Cure's board of directors, marking a key strategic alliance in radiation oncology. The firm maintains a lean structure with no reported revenue or employees, concentrating operations through its venture investments amid challenging market conditions reflected in its sub-ILA1 share price and stagnant performance.